United Kingdom (UK)
Recombinant monoclonal antibody to Bordetella pertussis lipooligosaccharide. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma HBp2.
Immunogen: The original antibody was raised from splenic lymphocytes isolated from fresh human spleen tissue, that were immunized in vitro against Bordetella pertussis lipooligosaccharide.
Specificity: This antibody is specific for B. pertussis strains 9340 and Tohama 1, but not other strains
Application Notes: The original antibody was used for a dot blot on different bacteria lysates. This antibody was used for a radioimmunoassay on live bacteria, this antibody bound to surface-exposed epitopes on B. pertussis strains 9340 and Tohama 1, but not other strains. The biological activity of this antibody against B. pertussis and B. bronchiseptica was assessed. It showed a high degree of killing on B. pertussis strain 9340. This antibody was used for an ELISA on B. pertussis OMP preparations (Brodeur et al., 1991; PMID:1721552).
Antibody first published in:
Brodeur et al. Biological activity of a human monoclonal antibody to Bordetella pertussis lipooligosaccharide Hum Antibodies Hybridomas. 1991 Oct;2(4):194-9. PMID:1721552
Note on publication:
The original paper generated heterohybridoma cell line HBp2 secreting human monoclonal antibody (hMAb) directed against Bordetella pertussis by fusing SP2/HPT heteromyeloma cells with human spleen lymphocytes, after in vitro stimulation for 6 days.